These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16144510)

  • 1. Ramipril in the treatment of vascular diseases.
    Rokoss MJ; Teo KK
    Expert Opin Pharmacother; 2005 Sep; 6(11):1911-9. PubMed ID: 16144510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramipril.
    Smith WH; Ball SG
    Int J Clin Pract; 2000 May; 54(4):255-60. PubMed ID: 10912316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on ramipril in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Am J Cardiovasc Drugs; 2003; 3(2):113-6. PubMed ID: 14727938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramipril: a review of its use in the prevention of cardiovascular outcomes.
    Warner GT; Perry CM
    Drugs; 2002; 62(9):1381-405. PubMed ID: 12076194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    Yusuf S
    Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.
    Lièvre M; Marre M; Chatellier G; Plouin P; Réglier J; Richardson L; Bugnard F; Vasmant D
    Control Clin Trials; 2000 Aug; 21(4):383-96. PubMed ID: 10913814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramipril for the prevention and treatment of cardiovascular disease.
    Vuong AD; Annis LG
    Ann Pharmacother; 2003 Mar; 37(3):412-9. PubMed ID: 12639174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.
    Mann JF
    Presse Med; 2005 Oct; 34(18):1303-8. PubMed ID: 16269994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
    ; Yusuf S; Sleight P; Pogue J; Bosch J; Davies R; Dagenais G
    N Engl J Med; 2000 Jan; 342(3):145-53. PubMed ID: 10639539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
    Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    Unger T
    Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
    Zimmermann M; Unger T
    Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
    Dinicolantonio JJ; Lavie CJ; O'Keefe JH
    Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of long-term therapy with ramipril in high-risk women.
    Lonn E; Roccaforte R; Yi Q; Dagenais G; Sleight P; Bosch J; Suhan P; Micks M; Probstfield J; Bernstein V; Yusuf S;
    J Am Coll Cardiol; 2002 Aug; 40(4):693-702. PubMed ID: 12204499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    Arnold JM; Yusuf S; Young J; Mathew J; Johnstone D; Avezum A; Lonn E; Pogue J; Bosch J;
    Circulation; 2003 Mar; 107(9):1284-90. PubMed ID: 12628949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II and trials of cardiovascular outcomes.
    Sleight P
    Am J Cardiol; 2002 Jan; 89(2A):11A-16A; discussion 16A-17A. PubMed ID: 11835905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.
    Anderson VR; Perry CM; Robinson DM
    Am J Cardiovasc Drugs; 2006; 6(6):417-32. PubMed ID: 17192135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.